drugset / Trial / NCT01284205
First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to compare the safety and efficacy of EN3348 (MCC) versus BCG as first line treatment in patients with non-muscle invasive bladder cancer that are at high risk for recurrence or progression.
Timeline
- Start
- 2010-01
- Primary completion
- 2014-02
- Completion
- 2017-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bacillus Calmette-Guérin | Vaccine | — | Other |
| Subject | Mycobacterial Cell-Wall DNA Complex | Unknown | 8 mg | Other |